Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Yuki IijimaMasao Omata

Abstract

Immunotherapy has become a treatment option for lung cancer. The utility of nivolumab as second-line treatment for non-small cell lung cancer has been proven, but predictive biomarkers influencing its efficacy remain unknown. This study involved 14 patients who were treated with nivolumab from February 1 to September 30, 2016. The early response of the level of circulating tumour DNA (ctDNA) after starting nivolumab was evaluated to ascertain whether it could predict treatment outcome. Of the 14 patients, six were responders and eight were non-responders. DNA was analysed in both tumour tissue and plasma samples. Only somatic mutations confirmed by analysis of tumour tissue were defined as ctDNA. ctDNA was detected more often in the serial plasma samples of patients with high tumour volume (TV) (p = 0.02). ctDNA was detected in seven cases; basal and serial ctDNA analysis revealed that a decrease in allelic frequency (AF) of ctDNA showed high-level correspondence with a good durable response. When "2 weeks" was set as a clinically significant time point, changes in representative mutations of each case, defined as one of the highest baseline AF, showed 100% concordance with the response. In patients with high TV, plasma analysi...Continue Reading

Citations

Jan 27, 2019·Cancers·Sotaro Otake, Taichiro Goto
Aug 31, 2019·Expert Review of Molecular Diagnostics·Ernest Y Lee, Rajan P Kulkarni
Sep 18, 2018·Oncoimmunology·Adrien CostantiniEtienne Giroux Leprieur
Jan 23, 2019·Journal of Gastroenterology·Shinya TakaokaMasao Omata
May 3, 2020·International Journal of Molecular Sciences·Taichiro Goto
Jul 28, 2018·Nature Reviews. Clinical Oncology·Luc CabelFrançois-Clément Bidard
May 6, 2020·Cancer Metastasis Reviews·Pieter A BoonstraAnna K L Reyners
Feb 10, 2019·Cancers·Alessia CimadamoreRodolfo Montironi
Jan 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mattia BoeriGabriella Sozzi
Nov 2, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen J BagleyErica L Carpenter
Dec 14, 2018·Cancer Research·Valsamo AnagnostouVictor E Velculescu
Sep 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew GeorgiadisMark Sausen
Jul 22, 2019·Cancer Treatment Reviews·Ting-Hui WuJames Chih-Hsin Yang
Feb 13, 2021·Cancers·Milana Bergamino SirvénMaggie C U Cheang
Aug 8, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Li WangXiaochun Zhang
Aug 15, 2021·Clinical Radiology·M K ThompsonJ D Brenton
Oct 14, 2021·Nature Reviews. Clinical Oncology·Filippo G Dall'OlioBenjamin Besse
Nov 25, 2021·Cancer Research·Julia-Christina StadlerKlaus Pantel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.